JP2023502843A5 - - Google Patents

Info

Publication number
JP2023502843A5
JP2023502843A5 JP2022519139A JP2022519139A JP2023502843A5 JP 2023502843 A5 JP2023502843 A5 JP 2023502843A5 JP 2022519139 A JP2022519139 A JP 2022519139A JP 2022519139 A JP2022519139 A JP 2022519139A JP 2023502843 A5 JP2023502843 A5 JP 2023502843A5
Authority
JP
Japan
Prior art keywords
sequence
fusion polypeptide
cancer
amino acid
acid residues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022519139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023502843A (ja
Filing date
Publication date
Priority claimed from GB201913804A external-priority patent/GB201913804D0/en
Application filed filed Critical
Publication of JP2023502843A publication Critical patent/JP2023502843A/ja
Publication of JP2023502843A5 publication Critical patent/JP2023502843A5/ja
Pending legal-status Critical Current

Links

JP2022519139A 2019-09-25 2020-09-25 癌を処置するために使用されるil-15融合ペプチド Pending JP2023502843A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201913804A GB201913804D0 (en) 2019-09-25 2019-09-25 Fusion polypeptides
GB1913804.9 2019-09-25
PCT/GB2020/052328 WO2021058973A1 (en) 2019-09-25 2020-09-25 Il-15 fusion peptides used to treat cancer

Publications (2)

Publication Number Publication Date
JP2023502843A JP2023502843A (ja) 2023-01-26
JP2023502843A5 true JP2023502843A5 (cg-RX-API-DMAC7.html) 2023-09-28

Family

ID=68425465

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022519139A Pending JP2023502843A (ja) 2019-09-25 2020-09-25 癌を処置するために使用されるil-15融合ペプチド

Country Status (9)

Country Link
US (1) US20220372097A1 (cg-RX-API-DMAC7.html)
EP (1) EP4034552A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023502843A (cg-RX-API-DMAC7.html)
CN (1) CN114651014A (cg-RX-API-DMAC7.html)
AU (1) AU2020351698A1 (cg-RX-API-DMAC7.html)
CA (1) CA3155100A1 (cg-RX-API-DMAC7.html)
GB (1) GB201913804D0 (cg-RX-API-DMAC7.html)
IL (1) IL291560A (cg-RX-API-DMAC7.html)
WO (1) WO2021058973A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11629340B2 (en) 2017-03-03 2023-04-18 Obsidian Therapeutics, Inc. DHFR tunable protein regulation
GB202304385D0 (en) 2023-03-24 2023-05-10 Prostate Cancer Res Combinatorial IL-15 therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
GB9614871D0 (en) 1996-07-15 1996-09-04 Smithkline Beecham Plc Compounds
US20070160578A1 (en) * 2005-12-14 2007-07-12 The Gov. Of The Usa As Represented By The Secretary Of The Dep. Of Health And Human Services Expansion of natural killer and CD8 T-cells with IL-15R/ligand activator complexes
GB0915519D0 (en) 2009-09-04 2009-10-07 King S College London Ntithrombotic compounds
AU2011317211B2 (en) * 2010-10-22 2015-04-16 Dana-Farber Cancer Institute, Inc. Discovery of regulatory T cells programmed to suppress an immune response
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
AU2018291497A1 (en) * 2017-06-30 2020-01-16 Xencor, Inc. Targeted heterodimeric Fc fusion proteins containing IL-15/IL-15Ra and antigen binding domains
JP7386161B2 (ja) * 2017-12-19 2023-11-24 ブレイズ バイオサイエンス, インコーポレイテッド 腫瘍ホーミング及び細胞透過性ペプチド免疫抗がん剤複合体、ならびにそれらの使用方法
MX387358B (es) * 2018-02-28 2025-03-18 Pfizer Variantes de il-15 y usos de las mismas
CA3090407A1 (en) * 2018-03-01 2019-09-06 Glycotope Gmbh Fusion protein constructs comprising an anti-muc1 antibody and il-15

Similar Documents

Publication Publication Date Title
US20240066096A1 (en) pHLIP® peptide mediated epitope tethering at cell surfaces
JP4480580B2 (ja) Wt1置換型ペプチド
EP2114993B1 (en) Vaccine
RU2020113032A (ru) Новые пептиды и комбинации пептидов для применения в иммунотерапии рака легких, в том числе немелкоклеточного рака легких (нмрл) и других видов рака
ES2398492T3 (es) Proteínas de fusión que comprenden los antígenos de rechazo tumoral NY-ESO-1 y LAGE-1
NZ281409A (en) Medicaments for cancer treatment using peptides based on a 9 AA epitiope derived from mage -3 that induces ctls
JP2010506826A5 (cg-RX-API-DMAC7.html)
JP2016538829A (ja) 低密度リポタンパク質受容体をコードするポリヌクレオチド
RU2009118432A (ru) Пептидные вакцины против рака с экспрессией полипептидов mphosph1 или depdc1
RU2020128838A (ru) Композиции и способы для индуцирования передачи сигнала белка, содержащего трехсторонний мотив, 16 (trim16)
JP2008530975A5 (cg-RX-API-DMAC7.html)
JP2010514669A5 (cg-RX-API-DMAC7.html)
US20200062811A1 (en) Yap protein inhibiting polypeptide and application thereof
US10441628B2 (en) High activity tumour inhibitor and preparation method and use thereof
AU2013295045B2 (en) CyaA-based chimeric proteins comprising a heterologous polypeptide and their uses in the induction of immune responses
CN100467063C (zh) 一类免疫佐剂及其在抗病毒疫苗或药物制备中的应用
RU2004122084A (ru) Пептиды для лечения рака, ассоциированного с папилломавирусом (hpv) человека, и других эпителиальных опухолей
RS58313B1 (sr) Himerni proteini na bazi hpv/cyaa i njihove upotrebe u indukovanju imunskih odgovora na hpv infekciju i hpv-indukovane poremećaje
CN110857315A (zh) 一种治疗肿瘤的多肽药物、衍生物及其使用方法
CN108250277B (zh) 微小rna31前体编码多肽的截短体在制备免疫调节药物中的应用
CN112142824B (zh) 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用
CN110305209B (zh) 用于治疗恶性肿瘤的多肽及其作为疫苗的用途
CN116262783A (zh) 胚胎干细胞来源的肿瘤抗原表位肽及其应用
TWI670280B (zh) 人類乳突病毒之脂質抗原及用於人類乳突病毒相關疾病之免疫治療組合物
AU2008206463B2 (en) Fusion proteins comprising the tumor rejection antigens NY-ESO-1 and LAGE-1